Vosoritide
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Vosoritide
- DrugBank Accession Number
- DB11928
- Background
Vosoritide has been used in trials studying the treatment of Achondroplasia.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Peptides - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Vosoritide
- External IDs
- BMN 111
- BMN-111
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Voxzogo Injection, powder, for solution 0.56 mg Subcutaneous Biomarin International Limited 2021-10-06 Not applicable EU 
Voxzogo Injection, powder, for solution 0.4 mg Subcutaneous Biomarin International Limited 2021-10-06 Not applicable EU Voxzogo Injection, powder, for solution 1.2 mg Subcutaneous Biomarin International Limited 2021-10-06 Not applicable EU
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7SE5582Q2P
- CAS number
- 1480724-61-5
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911258
- Wikipedia
- Vosoritide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Achondroplasia 1 3 Completed Treatment Achondroplasia 1 2 Active Not Recruiting Treatment Achondroplasia 2 2 Completed Treatment Achondroplasia 1 2 Enrolling by Invitation Treatment Achondroplasia 1 2 Recruiting Treatment Achondroplasia 1 2 Recruiting Treatment Short Stature 1 1 Completed Treatment Achondroplasia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Subcutaneous 0.4 mg Injection, powder, for solution Subcutaneous 0.56 mg Injection, powder, for solution Subcutaneous 1.2 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on October 20, 2016 21:01 / Updated on October 13, 2021 09:32